BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:LMB Seminar - De-novo discovery of macrocyclic peptides and pseudo
 -natural products for therapeutic innovation - Hiroaki Suga - The Universi
 ty of Tokyo
DTSTART:20250929T100000Z
DTEND:20250929T110000Z
UID:TALK225742@talks.cam.ac.uk
CONTACT:Scientific Meetings Co-ordinator
DESCRIPTION:Macrocyclic peptides possess a number of pharmacological chara
 cteristics distinct from other well-established therapeutic molecular clas
 ses\, resulting in a versatile drug modality with a unique profile of adva
 ntages. Macrocyclic peptides are accessible by not only chemical synthesis
  but also ribosomal synthesis. Particularly\, recent inventions of the gen
 etic code reprogramming integrated with mRNA-encoding display format\, ref
 erred to as RaPID (Random non-standard Peptides Integrated Discovery) syst
 em\, have enabled us to screen mass libraries consisting of over 1 trillio
 n members of non-standard peptides containing multiple non-proteinogenic a
 mino acids\, giving unique properties of macrocyclic pseudo-natural peptid
 es distinct from conventional peptides\, e.g. greater proteolytic stabilit
 y\, higher affinity (low nM to sub nM dissociation constants similar to an
 tibodies)\, and superior pharmacokinetics. The field is rapidly growing ev
 idenced by increasing interests from industrial sectors\, including mega-p
 harmas\, toward drug development efforts on macrocyclic peptides as a new 
 modality group. This lecture discusses their screening by the RaPID system
 \, and several showcases of therapeutic potentials of such molecules. This
  lecture also discusses the most recent advance in the display of de novo 
 pseudo-natural products generated by thiopeptide’s post-translationally 
 modifying enzymes.
LOCATION:In person in the Max Perutz Lecture Theatre (CB2 0QH) and via Zoo
 m link https://mrc-lmb-cam-ac-uk.zoom.us/j/96488916942?pwd=BpCGRwD8hD8ec89
 yfaJ0yKPmV3o6lv.1
END:VEVENT
END:VCALENDAR